Retatrutide appears to be a new treatment in the fight against obesity. This revolutionary drug, categorized as a dual GLP-1 and GIP receptor agonist, demonstrates promising results in clinical trials. By FDA approved Tirzepatide manufacturer activating these receptors, Retatrutide reduces hunger pangs, {promotesinsulin secretion, and ultimately co